Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, Hu W, McPhee F, Linaberry M, Yin PD, Swenson ES, Kumada H. Toyota J, et al. Among authors: takaguchi k. J Gastroenterol. 2017 Mar;52(3):385-395. doi: 10.1007/s00535-016-1245-6. Epub 2016 Aug 9. J Gastroenterol. 2017. PMID: 27502287 Clinical Trial.
Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
Ikeda F, Baba N, Takaguchi K, Kubota J, Miyoshi K, Fujioka S, Moritou Y, Takeuchi Y, Yasunaka T, Miyake Y, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Ikeda F, et al. Among authors: takaguchi k. J Med Virol. 2012 Oct;84(10):1562-70. doi: 10.1002/jmv.23371. J Med Virol. 2012. PMID: 22930504
Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.
Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, Izumi N. Toyoda H, et al. Among authors: takaguchi k. BMC Infect Dis. 2012 Nov 27;12:324. doi: 10.1186/1471-2334-12-324. BMC Infect Dis. 2012. PMID: 23181537 Free PMC article. Clinical Trial.
Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.
Shimada N, Toyoda H, Tsubota A, Ide T, Takaguchi K, Kato K, Kondoh M, Matsuyama K, Kumada T, Sata M. Shimada N, et al. Among authors: takaguchi k. J Gastroenterol. 2014 Nov;49(11):1485-94. doi: 10.1007/s00535-013-0918-7. Epub 2013 Nov 28. J Gastroenterol. 2014. PMID: 24287582 Clinical Trial.
Changes in hepatitis C virus genotype distribution in Japan.
Toyoda H, Kumada T, Takaguchi K, Shimada N, Tanaka J. Toyoda H, et al. Among authors: takaguchi k. Epidemiol Infect. 2014 Dec;142(12):2624-8. doi: 10.1017/S0950268814000478. Epub 2014 Mar 5. Epidemiol Infect. 2014. PMID: 24598252 Free PMC article.
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Kumada H, et al. Among authors: takaguchi k. Hepatology. 2014 Jun;59(6):2083-91. doi: 10.1002/hep.27113. Epub 2014 Apr 1. Hepatology. 2014. PMID: 24604476 Free PMC article. Clinical Trial.
234 results